Financing ·
On September 7, 2026, Lexaria Bioscience Corp. entered into inducement letter agreements with holders of existing…
LEXXLexaria Bioscience Corp.
On September 7, 2026, Lexaria Bioscience Corp. entered into inducement letter agreements with holders of existing common stock purchase warrants to exercise an aggregate of 453,969 warrants at a reduced price of $12.92 per share. The transaction generated approximately $5.9 million in gross proceeds for working capital and general corporate purposes. In consideration, the Company issued new unregistered Series A and Series B warrants to purchase up to 453,969 shares each, both carrying an exercise price of $12.67 per share and immediate exercisability. The closing is expected on September 9, 2026, with H.C. Wainwright & Co. acting as placement agent for a 7% fee plus warrants to purchase 15,889 shares. Lexaria Bioscience Corp. operates in the biotechnology industry, developing drug delivery platforms and formulations.